EUVIMEDAtrasti EUVIMED
Open access · CC BY 4.0

Real-world efficacy and tolerability of solifenacin for the treatment of neurogenic overactive bladder in patients with multiple sclerosis

Luca Orecchia, Eleonora Rosato, Petra Vogrig, Daniele Bianchi, Yuri Cavaleri, Giorgia Mataluni, Doriana Landi, Maddalena Dal Pozzo, Carolina Gabri Nicoletti, Girolama Alessandra Marfia, Enrico Finazzi Agrò

Bladder · 2026-03-06 · e21200084

DOI: 10.14440/bladder.0353 ↗

At a glance

Journal article in Bladder, published online on 2026-03-06. Written by Luca Orecchia and 10 co-authors. The full text is freely available (open access, CC BY 4.0).

SantraukaBibliografiniai duomenysCiteRelated studies

Abstract (original language)

Background

Evidence on the use of antimuscarinic agents, such as solifenacin, for the treatment of neurogenic overactive bladder (nOAB) in patients with multiple sclerosis (MS) mainly derives from small, selected populations or industry-sponsored trials. Real-world data on its effectiveness and tolerability in unselected MS cohorts remain limited.

Objective

The aim of this study is to evaluate the efficacy and safety of solifenacin in a real-world population of MS patients managed in an outpatient setting.

Methods

We conducted a retrospective analysis of consecutive MS patients treated with solifenacin at any point in their urological treatment course. Demographic, clinical, and urodynamic data were collected, including lower urinary tract symptoms (LUTS), uroflowmetry parameters, and treatment-related adverse drug reactions.

Results

Seventy-four patients were included, of whom 71.6% were female, with a mean age of 49 ± 10.7 years. Solifenacin was prescribed as first-line therapy in 82.4% of cases. During treatment, resolution of nOAB symptoms was achieved in 63.5% of patients, while urge urinary incontinence decreased to 35.1% during treatment. Uroflowmetry parameters and post-void residual volumes remained stable, indicating a negligible impact on voiding efficiency. Fourteen mild adverse drug reactions were reported, which were mainly constipation and transient urinary retention.

Conclusion

This study confirms that solifenacin is an effective and well-tolerated treatment for nOAB in MS patients, with a favorable safety profile and minimal impact on bladder emptying. Unlike previous studies based on highly selected populations, our results provide pragmatic evidence from everyday clinical practice, supporting solifenacin as a reliable first-line option in neurogenic LUTS management among MS patients.

Cite

APA

Orecchia, L., Rosato, E., Vogrig, P., Bianchi, D., Cavaleri, Y., Mataluni, G., Landi, D., Pozzo, M. D., Nicoletti, C. G., Marfia, G. A., & Agrò, E. F. (2026). Real-world efficacy and tolerability of solifenacin for the treatment of neurogenic overactive bladder in patients with multiple sclerosis. Bladder, 0(0), e21200084. https://doi.org/10.14440/bladder.0353

Vancouver

Orecchia L, Rosato E, Vogrig P, Bianchi D, Cavaleri Y, Mataluni G, et al. Real-world efficacy and tolerability of solifenacin for the treatment of neurogenic overactive bladder in patients with multiple sclerosis. Bladder. 2026;0(0):e21200084. doi:10.14440/bladder.0353

BibTeX
@article{Orecchia2026,
  author = {Orecchia, Luca and Rosato, Eleonora and Vogrig, Petra and Bianchi, Daniele and Cavaleri, Yuri and Mataluni, Giorgia and Landi, Doriana and Pozzo, Maddalena Dal and Nicoletti, Carolina Gabri and Marfia, Girolama Alessandra and Agrò, Enrico Finazzi},
  title = {Real-world efficacy and tolerability of solifenacin for the treatment of neurogenic overactive bladder in patients with multiple sclerosis},
  journal = {Bladder},
  year = {2026},
  volume = {0},
  number = {0},
  pages = {e21200084},
  doi = {10.14440/bladder.0353}
}
Start for free →